Ausgabe 3/2017
Inhalt (11 Artikel)
Towards a Model-Based Dose Recommendation for Doxorubicin in Children
Swantje Völler, Georg Hempel, Gudrun Würthwein, Alan V. Boddy, Miriam Krischke, Nicolas André, Maurizio D’Incalci, Gianni Bisogno, Joachim Boos
Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union
Ryosuke Kuribayashi, Toru Yamaguchi, Hanaka Sako, Tomoko Takishita, Kazunori Takagi
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
Sven Wind, David Schnell, Thomas Ebner, Matthias Freiwald, Peter Stopfer
Clinical Pharmacokinetics and Pharmacodynamics of Safinamide
Thomas Müller, Paul Foley
A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations
John P. Prybylski
Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?
Elisa A. M. Calvier, Elke H. J. Krekels, Pyry A. J. Välitalo, Amin Rostami-Hodjegan, Dick Tibboel, Meindert Danhof, Catherijne A. J. Knibbe
Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients
Sheima Farag, Remy B. Verheijen, J. Martijn Kerst, Annemiek Cats, Alwin D. R. Huitema, Neeltje Steeghs
Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients
Huixin Yu, Nielka van Erp, Sander Bins, Ron H. J. Mathijssen, Jan H. M. Schellens, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema
Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure
Sander Bins, Karel Eechoute, Jacqueline S. L. Kloth, Femke M. de Man, Astrid W. Oosten, Peter de Bruijn, Stefan Sleijfer, Ron H. J. Mathijssen